AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
January 24, 2022SHARE YOUR BOTOX® COSMETIC STORY FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN
-
January 21, 2022- SKYRIZI® (risankizumab-rzaa) met the primary endpoint of ACR20 at week 24 in two pivotal studies, demonstrating significant improvement in joint symptoms, including swollen, tender and painful joints, compared to placebo[1,2,3]
-
January 14, 2022- Approval of two dose strengths (15 mg and 30 mg) supported by efficacy and safety data from one of the largest registrational Phase 3 programs in atopic dermatitis, with more than 2,500 patients evaluated across three studies[1]
-
January 07, 2022- Submissions supported by Phase 3 study in which upadacitinib (RINVOQ®) demonstrated significant improvements in signs and symptoms as well as physical function and disease activity versus placebo
-
January 04, 2022- Teliso-V, an investigational antibody-drug conjugate (ADC), is being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression
-
December 16, 2021-- Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite --
-
December 14, 2021- Approval backed by two Phase 3 clinical studies where RINVOQ (15 mg, once daily) showed efficacy across multiple measures of disease activity in active psoriatic arthritis (PsA) with a safety profile consistent with that seen in rheumatoid arthritis (RA) [1]
-
December 09, 2021- Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye's ability to focus on near objects and affects nearly half of the U.S. adult population, usually over age 40
-
December 06, 2021- In U-EXCEED, a significantly higher proportion of patients with moderate to severe Crohn's disease treated with upadacitinib (45 mg once daily for induction) achieved both primary endpoints of clinical remission[a,b] and endoscopic response[c] compared to placebo at week 12[1]
-
November 30, 2021- Submission supported by three pivotal Phase 3 studies in which risankizumab demonstrated significant improvements in clinical remission and endoscopic response as both induction and maintenance therapy[1,2]
-
November 23, 2021
-
November 23, 2021
-
November 18, 2021- A new literature review published in Advances in Therapy reported that for patients with rheumatoid arthritis (RA), achieving remission was associated with medical cost savings compared with other disease activity levels
-
November 17, 2021- Approval supported by data from two Phase 3 studies evaluating SKYRIZI in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2[1-3]
-
November 15, 2021POWERED BY ALLĒ, CONSUMERS ARE ENCOURAGED TO SHARE BOTOX COSMETIC BOGO EXCITEMENT WITH FRIENDS AND FAMILY
-
November 10, 2021
-
November 09, 2021- Post-hoc analyses of the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials show people with active psoriatic arthritis (PsA) demonstrated greater clinical responses related to axial involvement when treated with upadacitinib (RINVOQ®) compared to placebo at week 24[1]
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
